Download PDF
Semin Reprod Med 2009; 27(4): 306-315
DOI: 10.1055/s-0029-1225258
© Thieme Medical Publishers

Androgens in Polycystic Ovary Syndrome: The Role of Exercise and Diet

Francesco Giallauria1 , Stefano Palomba2 , Carlo Vigorito1 , Maria Giovanna Tafuri3 , Annamaria Colao4 , Gaetano Lombardi4 , Francesco Orio4 , 5
  • 1Department of Clinical Medicine, Cardiovascular and Immunological Sciences, University of Naples “Federico II,” Naples, Italy
  • 2Department of Obstetrics and Gynaecology, University of Catanzaro “Magna Graecia,” Catanzaro, Italy
  • 3Teaching and Methods of Sportive Activity, Faculty of Exercise Sciences, University of Naples “Parthenope,” Naples, Italy
  • 4Department of Molecular & Clinical Endocrinology and Oncology, University of Naples “Federico II,” Naples, Italy
  • 5Endocrinology, Faculty of Exercise Sciences, University of Naples “Parthenope,” Naples, Italy
Further Information

Publication History

Publication Date:
15 June 2009 (online)

    Permissions and Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women and is characterized by chronic ovulatory dysfunction and hyperandrogenism. Clinical studies have shown that hyperandrogenism is linked with insulin resistance/metabolic syndrome in PCOS women. This review article summarizes the several potential mechanisms for the association of androgen excess with insulin resistance, including both direct and indirect actions of androgens on insulin target tissues. This review article also focuses on the beneficial effects of exercise training and diet on glucose metabolism and hyperandrogenism in PCOS women, pointing out that whether in conjunction with pharmacotherapy or as a stand-alone treatment, diet and exercise training represent a fundamental strategy in the treatment of PCOS women.

KEYWORDS

Polycystic ovary syndrome - exercise training - diet - hyperandrogenism - insulin resistance

REFERENCES

  • 1 Ehrmann D A. Polycystic ovary syndrome.  N Engl J Med. 2005;  352 1223-1236
    CrossrefPubMedGoogle Scholar
  • 2 Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span.  J Clin Endocrinol Metab. 2005;  90 4650-4658
    CrossrefPubMedGoogle Scholar
  • 3 Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications.  Expert Rev Mol Med. 2008;  10 e3
    CrossrefPubMedGoogle Scholar
  • 4 The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertil Steril. 2004;  81 19-25
    PubMedGoogle Scholar
  • 5 Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome.  J Cardiovasc Med (Hagerstown). 2008;  9 987-992
    CrossrefPubMedGoogle Scholar
  • 6 Hoffman L K, Ehrmann D A. Cardiometabolic features of polycystic ovary syndrome.  Nat Clin Pract Endocrinol Metab. 2008;  4 215-222
    CrossrefPubMedGoogle Scholar
  • 7 Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome.  Int J Obes (Lond). 2007;  31(Suppl 2) S8-S13; discussion S31–S32
    CrossrefPubMedGoogle Scholar
  • 8 Schröder A K, Tauchert S, Ortmann O, Diedrich K, Weiss J M. Insulin resistance in patients with polycystic ovary syndrome.  Ann Med. 2004;  36 426-439
    PubMedGoogle Scholar
  • 9 Chen M J, Yang W S, Yang J H, Chen C L, Ho H N, Yang Y S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.  Hypertension. 2007;  49 1442-1447
    CrossrefPubMedGoogle Scholar
  • 10 Orio Jr F, Giallauria F, Palomba S et al.. Cardiopulmonary impairment in young women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91 2967-2971
    CrossrefPubMedGoogle Scholar
  • 11 Orio Jr F, Palomba S, Giallauria F, Colao A, Vigorito C. Impaired cardiopulmonary parameters in young women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 2007;  66 152-153
    PubMedGoogle Scholar
  • 12 Giallauria F, Palomba S, Manguso F et al.. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 2008;  68 88-93
    PubMedGoogle Scholar
  • 13 Kelly C C, Lyall H, Petrie J R, Gould G W, Connell J M, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86 2453-2455
    CrossrefPubMedGoogle Scholar
  • 14 Giallauria F, Orio F, Lombardi G et al.. Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study.  J Ovarian Res. 2009;  2 3
    CrossrefPubMedGoogle Scholar
  • 15 Rossi B, Sukalich S, Droz J et al.. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.  J Clin Endocrinol Metab. 2008;  93 4780-4786
    CrossrefPubMedGoogle Scholar
  • 16 Barbieri R L, Makris A, Randall R W, Daniels G, Kistner R W, Ryan K J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.  J Clin Endocrinol Metab. 1986;  62 904-910
    CrossrefPubMedGoogle Scholar
  • 17 Nestler J E, Powers L P, Matt D W et al.. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 1991;  72 83-89
    CrossrefPubMedGoogle Scholar
  • 18 Nestler J E, Jakubowicz D J, de Vargas A F, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.  J Clin Endocrinol Metab. 1998;  83 2001-2005
    CrossrefPubMedGoogle Scholar
  • 19 Codner E, Iñíguez G, Villarroel C et al.. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus.  J Clin Endocrinol Metab. 2007;  92 4742-4746
    CrossrefPubMedGoogle Scholar
  • 20 Codner E, Escobar-Morreale H F. Clinical review: hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.  J Clin Endocrinol Metab. 2007;  92 1209-1216
    CrossrefPubMedGoogle Scholar
  • 21 Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS).  J Steroid Biochem Mol Biol. 2008;  109 242-246
    CrossrefPubMedGoogle Scholar
  • 22 Legro R S, Gnatuk C L, Kunselman A R, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.  J Clin Endocrinol Metab. 2005;  90 3236-3242
    CrossrefPubMedGoogle Scholar
  • 23 Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR Polycystic Ovary Syndrome. Boston, MA; Blackwell Scientific 1992: 377-384
    Google Scholar
  • 24 Azziz R, Carmina E, Dewailly D Androgen Excess Society et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.  J Clin Endocrinol Metab. 2006;  91 4237-4245
    Google Scholar
  • 25 Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.  J Clin Endocrinol Metab. 2006;  91 781-785
    CrossrefPubMedGoogle Scholar
  • 26 Auchus R J, Rainey W E. Adrenarche - physiology, biochemistry and human disease.  Clin Endocrinol (Oxf). 2004;  60 288-296
    CrossrefPubMedGoogle Scholar
  • 27 Flück C E, Miller W L, Auchus R J. The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway.  J Clin Endocrinol Metab. 2003;  88 3762-3766
    CrossrefPubMedGoogle Scholar
  • 28 Doi S A, Al-Zaid M, Towers P A, Scott C J, Al-Shoumer K A. Steroidogenic alterations and adrenal androgen excess in PCOS.  Steroids. 2006;  71 751-759
    CrossrefPubMedGoogle Scholar
  • 29 Nakajin S, Shively J E, Yuan P M, Hall P F. Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17 alpha-hydroxylase and c17,20-lyase) associated with one protein.  Biochemistry. 1981;  20 4037-4042
    CrossrefPubMedGoogle Scholar
  • 30 Lin D, Harikrishna J A, Moore C C, Jones K L, Miller W L. Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency.  J Biol Chem. 1991;  266 15992-15998
    PubMedGoogle Scholar
  • 31 Zuber M X, Simpson E R, Waterman M R. Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells.  Science. 1986;  234 1258-1261
    CrossrefPubMedGoogle Scholar
  • 32 Penning T M. Molecular endocrinology of hydroxysteroid dehydrogenases.  Endocr Rev. 1997;  18 281-305
    CrossrefPubMedGoogle Scholar
  • 33 Nelson V L, Qin K N, Rosenfield R L et al.. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2001;  86 5925-5933
    CrossrefPubMedGoogle Scholar
  • 34 Carbunaru G, Prasad P, Scoccia B et al.. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.  J Clin Endocrinol Metab. 2004;  89 783-794
    CrossrefPubMedGoogle Scholar
  • 35 Loughlin T, Cunningham S, Moore A, Culliton M, Smyth P P, McKenna T J. Adrenal abnormalities in polycystic ovary syndrome.  J Clin Endocrinol Metab. 1986;  62 142-147
    PubMedGoogle Scholar
  • 36 Kumar A, Woods K S, Bartolucci A A, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).  Clin Endocrinol (Oxf). 2005;  62 644-649
    CrossrefPubMedGoogle Scholar
  • 37 Carmina E, Lobo R A. Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients.  Gynecol Endocrinol. 1990;  4 225-232
    CrossrefPubMedGoogle Scholar
  • 38 Gonzalez F. Adrenal involvement in polycystic ovary syndrome.  Semin Reprod Endocrinol. 1997;  15 137-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Carmina E, Gonzalez F, Chang L, Lobo R A. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome.  Obstet Gynecol. 1995;  85 971-976
    CrossrefPubMedGoogle Scholar
  • 40 Matteri R K, Stanczyk F Z, Cassidenti D L, Paulson R J, Lobo R A. The ovarian contribution to peripherally derived serum C19 conjugates.  J Clin Endocrinol Metab. 1992;  75 768-772
    CrossrefPubMedGoogle Scholar
  • 41 Gonzalez F, Hatala D A, Speroff L. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.  Am J Obstet Gynecol. 1991;  165 535-545
    PubMedGoogle Scholar
  • 42 Kahsar-Miller M, Boots L R, Bartolucci A, Azziz R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.  Fertil Steril. 2004;  82 973-975
    CrossrefPubMedGoogle Scholar
  • 43 Witchel S F, Kahsar-Miller M, Aston C E, White C, Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess.  Fertil Steril. 2005;  83 371-375
    CrossrefPubMedGoogle Scholar
  • 44 Guido M, Romualdi D, Suriano R et al.. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.  Hum Reprod. 2004;  19 534-539
    CrossrefPubMedGoogle Scholar
  • 45 Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?.  Diabetes Metab Res Rev. 2008;  24 520-532
    CrossrefPubMedGoogle Scholar
  • 46 Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome.  Biochimie. 2005;  87 39-43
    CrossrefPubMedGoogle Scholar
  • 47 Pasquali R. Obesity and androgens: facts and perspectives.  Fertil Steril. 2006;  85 1319-1340
    CrossrefPubMedGoogle Scholar
  • 48 Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men.  Clin Endocrinol (Oxf). 2005;  63 239-250
    CrossrefPubMedGoogle Scholar
  • 49 Ding E L, Song Y, Malik V S, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.  JAMA. 2006;  295 1288-1299
    CrossrefPubMedGoogle Scholar
  • 50 Dunn J F, Nisula B C, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.  J Clin Endocrinol Metab. 1981;  53 58-68
    CrossrefPubMedGoogle Scholar
  • 51 Pugeat M, Crave J C, Elmidani M et al.. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin.  J Steroid Biochem Mol Biol. 1991;  40 841-849
    CrossrefPubMedGoogle Scholar
  • 52 Khosla S. Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action?.  J Clin Endocrinol Metab. 2006;  91 4764-4766
    CrossrefPubMedGoogle Scholar
  • 53 Rosner W, Auchus R J, Azziz R, Sluss P M, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.  J Clin Endocrinol Metab. 2007;  92 405-413
    CrossrefPubMedGoogle Scholar
  • 54 Liu Y, Ding J, Bush T L et al.. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation.  Am J Epidemiol. 2001;  154 489-494
    CrossrefPubMedGoogle Scholar
  • 55 Reinecke H, Bogdanski J, Woltering A et al.. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women.  Am J Cardiol. 2002;  90 364-368
    CrossrefPubMedGoogle Scholar
  • 56 Bernini G P, Sgro' M, Moretti A et al.. Endogenous androgens and carotid intimal-medial thickness in women.  J Clin Endocrinol Metab. 1999;  84 2008-2012
    CrossrefPubMedGoogle Scholar
  • 57 Cascella T, Palomba S, De Sio I et al.. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome.  Hum Reprod. 2008;  23 153-159
    PubMedGoogle Scholar
  • 58 Shpakov A O, Pertseva M N. Structural and functional characterization of insulin receptor substrate proteins and the molecular mechanisms of their interaction with insulin superfamily tyrosine kinase receptors and effector proteins.  Membr Cell Biol. 2000;  13 455-484
    PubMedGoogle Scholar
  • 59 DeFronzo R A, Jacot E, Jequier E, Maeder E, Wahren J, Felber J P. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization.  Diabetes. 1981;  30 1000-1007
    CrossrefPubMedGoogle Scholar
  • 60 Abel E D, Peroni O, Kim J K et al.. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver.  Nature. 2001;  409 729-733
    CrossrefPubMedGoogle Scholar
  • 61 Mahajan D K. Polycystic ovarian disease: animal models.  Endocrinol Metab Clin North Am. 1988;  17 705-732
    PubMedGoogle Scholar
  • 62 Mannerås L, Cajander S, Holmäng A et al.. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome.  Endocrinology. 2007;  148 3781-3791
    CrossrefPubMedGoogle Scholar
  • 63 Holmäng A, Svedberg J, Jennische E, Björntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats.  Am J Physiol. 1990;  259(4 Pt 1) E555-E560
    PubMedGoogle Scholar
  • 64 Holmäng A, Larsson B-M, Brzezinska Z, Björntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats.  Am J Physiol. 1992;  262(6 Pt 1) E851-E855
    PubMedGoogle Scholar
  • 65 Holmäng A, Niklasson M, Rippe B, Lönnroth P. Insulin insensitivity and delayed transcapillary delivery of insulin in oophorectomized rats treated with testosterone.  Acta Physiol Scand. 2001;  171 427-438
    CrossrefPubMedGoogle Scholar
  • 66 Rincon J, Holmäng A, Wahlström E O et al.. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment.  Diabetes. 1996;  45 615-621
    CrossrefPubMedGoogle Scholar
  • 67 Bolduc C, Larose M, Yoshioka M et al.. Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression.  J Mol Endocrinol. 2004;  33 429-444
    CrossrefPubMedGoogle Scholar
  • 68 Pedersen S B, Fuglsig S, Sjøgren P, Richelsen B. Identification of steroid receptors in human adipose tissue.  Eur J Clin Invest. 1996;  26 1051-1056
    CrossrefPubMedGoogle Scholar
  • 69 Dieudonne M N, Pecquery R, Boumediene A, Leneveu M C, Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids.  Am J Physiol. 1998;  274(6 Pt 1) C1645-C1652
    PubMedGoogle Scholar
  • 70 Joyner J, Hutley L, Cameron D. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes.  Horm Metab Res. 2002;  34 223-228
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Moghetti P, Tosi F, Castello R et al.. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.  J Clin Endocrinol Metab. 1996;  81 952-960
    CrossrefPubMedGoogle Scholar
  • 72 Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome.  J Clin Endocrinol Metab. 1990;  70 699-704
    PubMedGoogle Scholar
  • 73 Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba A J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.  J Clin Endocrinol Metab. 1998;  83 2699-2705
    CrossrefPubMedGoogle Scholar
  • 74 Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson P O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.  Hum Reprod. 1998;  13 2706-2711
    CrossrefPubMedGoogle Scholar
  • 75 Krotkiewski M, Landin K, Dahlgren E, Janson P O, Holm G. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS.  Gynecol Obstet Invest. 2003;  55 88-95
    CrossrefPubMedGoogle Scholar
  • 76 Elkind-Hirsch K E, Valdes C T, Malinak L R. Insulin resistance improves in hyperandrogenic women treated with Lupron.  Fertil Steril. 1993;  60 634-641
    PubMedGoogle Scholar
  • 77 Cagnacci A, Paoletti A M, Arangino S, Melis G B, Volpe A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism.  Hum Reprod. 1999;  14 893-897
    CrossrefPubMedGoogle Scholar
  • 78 Lanzone A, Fulghesu A M, Andreani C L et al.. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.  Hum Reprod. 1990;  5 143-149
    PubMedGoogle Scholar
  • 79 Gadir A A, Khatim M S, Mowafi R S, Alnaser H M, Alzaid H G, Shaw R W. Hormonal changes in patients with polycystic ovarian disease after ovarian electrocautery or pituitary desensitization.  Clin Endocrinol (Oxf). 1990;  32 749-754
    PubMedGoogle Scholar
  • 80 Tropeano G, Liberale I, Vuolo I P et al.. Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome.  J Endocrinol Invest. 1997;  20 220-224
    PubMedGoogle Scholar
  • 81 Zulian E, Sartorato P, Benedini S et al.. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.  J Endocrinol Invest. 2005;  28 49-53
    CrossrefPubMedGoogle Scholar
  • 82 Gambineri A, Patton L, Vaccina A et al.. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.  J Clin Endocrinol Metab. 2006;  91 3970-3980
    CrossrefPubMedGoogle Scholar
  • 83 Gambineri A, Pelusi C, Genghini S et al.. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 2004;  60 241-249
    CrossrefPubMedGoogle Scholar
  • 84 Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.  Fertil Steril. 2008;  89 899-906
    CrossrefPubMedGoogle Scholar
  • 85 Florakis D, Diamanti-Kandarakis E, Katsikis I et al.. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.  Int J Obes (Lond). 2008;  32 692-699
    CrossrefPubMedGoogle Scholar
  • 86 Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2008;  93 2670-2678
    CrossrefPubMedGoogle Scholar
  • 87 Moran L, Norman R J. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome.  Best Pract Res Clin Obstet Gynaecol. 2004;  18 719-736
    CrossrefPubMedGoogle Scholar
  • 88 Moran L J, Brinkworth G D, Norman R J. Dietary therapy in polycystic ovary syndrome.  Semin Reprod Med. 2008;  26 85-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 89 Palomba S, Giallauria F, Falbo A et al.. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study.  Hum Reprod. 2008;  23 642-650
    CrossrefPubMedGoogle Scholar
  • 90 Moran L J, Noakes M, Clifton P M, Tomlinson L, Galletly C, Norman R J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 812-819
    CrossrefPubMedGoogle Scholar
  • 91 Norman R J, Davies M J, Lord J, Moran L J. The role of lifestyle modification in polycystic ovary syndrome.  Trends Endocrinol Metab. 2002;  13 251-257
    CrossrefPubMedGoogle Scholar
  • 92 Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women.  Hum Reprod. 1996;  11 1884-1891
    PubMedGoogle Scholar
  • 93 Guzick D S, Wing R, Smith D, Berga S L, Winters S J. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.  Fertil Steril. 1994;  61 598-604
    PubMedGoogle Scholar
  • 94 Huber-Buchholz M M, Carey D G, Norman R J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.  J Clin Endocrinol Metab. 1999;  84 1470-1474
    CrossrefPubMedGoogle Scholar
  • 95 Clark A M, Ledger W, Galletly C et al.. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women.  Hum Reprod. 1995;  10 2705-2712
    PubMedGoogle Scholar
  • 96 Clark A M, Thornley B, Tomlinson L, Galletley C, Norman R J. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.  Hum Reprod. 1998;  13 1502-1505
    CrossrefPubMedGoogle Scholar
  • 97 Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome.  BJOG. 2006;  113 1203-1209
    PubMedGoogle Scholar
  • 98 Kiddy D S, Hamilton-Fairley D, Bush A et al.. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 1992;  36 105-111
    CrossrefPubMedGoogle Scholar
  • 99 Hamilton-Fairley D, Kiddy D, Anyaoku V, Koistinen R, Seppälä M, Franks S. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction.  Clin Endocrinol (Oxf). 1993;  39 363-367
    CrossrefPubMedGoogle Scholar
  • 100 Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome.  Appl Physiol Nutr Metab. 2006;  31 384-391
    CrossrefPubMedGoogle Scholar
  • 101 Thomson R L, Buckley J D, Noakes M, Clifton P M, Norman R J, Brinkworth G D. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2008;  93 3373-3380
    CrossrefPubMedGoogle Scholar
  • 102 Vigorito C, Giallauria F, Palomba S et al.. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  92 1379-1384
    CrossrefPubMedGoogle Scholar
  • 103 Giallauria F, Palomba S, Maresca L et al.. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS).  Clin Endocrinol (Oxf). 2008;  69 792-798
    CrossrefPubMedGoogle Scholar
  • 104 Orio F, Giallauria F, Palomba S et al.. Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women.  Clin Endocrinol (Oxf). 2008;  68 976-981
    CrossrefPubMedGoogle Scholar

Orio FrancescoM.D. Ph.D. 

Department of Molecular & Clinical Endocrinology and Oncology

University of Naples “Federico II,” Naples, Italy

Email: francescoorio@virgilio.it

      >